Seres Therapeutics (NASDAQ:MCRB) Stock Crosses Above 50-Day Moving Average – Here’s What Happened

Seres Therapeutics, Inc. (NASDAQ:MCRB) crossed above its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of $0.81 and traded as high as $0.85. Seres Therapeutics shares last traded at $0.83, with a volume of 1,538,519 shares.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on MCRB shares. JPMorgan Chase & Co. downgraded shares of Seres Therapeutics from a “neutral” rating to an “underweight” rating in a research report on Thursday, October 24th. StockNews.com lowered Seres Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, November 27th. Canaccord Genuity Group reissued a “buy” rating and issued a $10.00 target price on shares of Seres Therapeutics in a report on Thursday, November 14th. Finally, Chardan Capital reissued a “buy” rating and issued a $1.25 target price on shares of Seres Therapeutics in a research report on Wednesday, November 13th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and two have issued a buy rating to the company. According to MarketBeat.com, Seres Therapeutics has a consensus rating of “Hold” and a consensus price target of $5.08.

Seres Therapeutics Stock Up 7.4 %

The firm has a market cap of $154.59 million, a price-to-earnings ratio of -3.94 and a beta of 2.07. The business has a 50 day moving average price of $0.82 and a 200-day moving average price of $0.90.

Institutional Trading of Seres Therapeutics

Several hedge funds have recently bought and sold shares of MCRB. Virtu Financial LLC increased its position in shares of Seres Therapeutics by 44.8% during the 3rd quarter. Virtu Financial LLC now owns 58,791 shares of the biotechnology company’s stock valued at $56,000 after purchasing an additional 18,191 shares during the period. Geode Capital Management LLC boosted its stake in Seres Therapeutics by 22.5% during the third quarter. Geode Capital Management LLC now owns 1,388,639 shares of the biotechnology company’s stock valued at $1,314,000 after buying an additional 255,014 shares in the last quarter. State Street Corp boosted its stake in Seres Therapeutics by 12.9% during the third quarter. State Street Corp now owns 383,248 shares of the biotechnology company’s stock valued at $363,000 after buying an additional 43,700 shares in the last quarter. Providence Wealth Advisors LLC grew its holdings in Seres Therapeutics by 29.2% during the third quarter. Providence Wealth Advisors LLC now owns 98,500 shares of the biotechnology company’s stock worth $93,000 after acquiring an additional 22,250 shares during the period. Finally, FMR LLC raised its position in Seres Therapeutics by 0.6% in the third quarter. FMR LLC now owns 22,857,260 shares of the biotechnology company’s stock worth $21,625,000 after acquiring an additional 140,096 shares in the last quarter. 59.34% of the stock is currently owned by institutional investors.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.